{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T06:00:50Z","timestamp":1761976850125,"version":"build-2065373602"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2013,8,15]],"date-time":"2013-08-15T00:00:00Z","timestamp":1376524800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s00520-013-1926-0","type":"journal-article","created":{"date-parts":[[2013,8,14]],"date-time":"2013-08-14T02:35:18Z","timestamp":1376447718000},"page":"3425-3431","source":"Crossref","is-referenced-by-count":15,"title":["Palonosetron and prednisolone for the prevention of nausea and emesis during fractionated radiotherapy and 5\u00a0cycles of concomitant weekly cisplatin\u2014a phase II study"],"prefix":"10.1007","volume":"21","author":[{"given":"Christina H.","family":"Ruhlmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Belli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f8rn","family":"Herrstedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,8,15]]},"reference":[{"key":"1926_CR1","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1200\/JCO.1998.16.4.1318","volume":"16","author":"TG Wendt","year":"1998","unstructured":"Wendt TG, Grabenbauer GG, Rodel CM et al (1998) Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 16:1318\u20131324","journal-title":"J Clin Oncol"},{"key":"1926_CR2","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1056\/NEJM199904153401503","volume":"340","author":"HM Keys","year":"1999","unstructured":"Keys HM, Bundy BN, Stehman FB et al (1999) Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340:1154\u20131161","journal-title":"N Engl J Med"},{"key":"1926_CR3","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ajog.2007.08.003","volume":"197","author":"FB Stehman","year":"2007","unstructured":"Stehman FB, Ali S, Keys HM et al (2007) Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial. Am J Obstet Gynecol 197:503, e501-506","journal-title":"Am J Obstet Gynecol"},{"key":"1926_CR4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2003.01.008","volume":"21","author":"DJ Adelstein","year":"2003","unstructured":"Adelstein DJ, Li Y, Adams GL et al (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92\u201398","journal-title":"J Clin Oncol"},{"key":"1926_CR5","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2000.18.8.1606","volume":"18","author":"WA Peters 3rd","year":"2000","unstructured":"Peters WA 3rd, Liu PY, Barrett RJ 2nd et al (2000) Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18:1606\u20131613","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"1926_CR6","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1007\/s00520-010-0950-6","volume":"19","author":"PC Feyer","year":"2011","unstructured":"Feyer PC, Maranzano E, Molassiotis A et al (2011) Radiotherapy-induced nausea and vomiting (RINV): MASCC\/ESMO guideline for antiemetics in radiotherapy: update 2009. Support Care Cancer 19(Suppl 1):S5\u201314","journal-title":"Support Care Cancer"},{"issue":"Suppl 5","key":"1926_CR7","doi-asserted-by":"crossref","first-page":"v232","DOI":"10.1093\/annonc\/mdq194","volume":"21","author":"F Roila","year":"2010","unstructured":"Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232\u2013243","journal-title":"Ann Oncol"},{"key":"1926_CR8","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","volume":"29","author":"E Basch","year":"2011","unstructured":"Basch E, Prestrud AA, Hesketh PJ et al (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189\u20134198","journal-title":"J Clin Oncol"},{"key":"1926_CR9","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","volume":"21","author":"PJ Hesketh","year":"2003","unstructured":"Hesketh PJ, Grunberg SM, Gralla RJ et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin\u2013the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112\u20134119","journal-title":"J Clin Oncol"},{"key":"1926_CR10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1586\/era.09.175","volume":"10","author":"C Ruhlmann","year":"2010","unstructured":"Ruhlmann C, Herrstedt J (2010) Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther 10:137\u2013148","journal-title":"Expert Rev Anticancer Ther"},{"key":"1926_CR11","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/cncr.11817","volume":"98","author":"P Eisenberg","year":"2003","unstructured":"Eisenberg P, Figueroa-Vadillo J, Zamora R et al (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98:2473\u20132482","journal-title":"Cancer"},{"key":"1926_CR12","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/annonc\/mdg417","volume":"14","author":"R Gralla","year":"2003","unstructured":"Gralla R, Lichinitser M, Van Der Vegt S et al (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570\u20131577","journal-title":"Ann Oncol"},{"key":"1926_CR13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(08)70313-9","volume":"10","author":"M Saito","year":"2009","unstructured":"Saito M, Aogi K, Sekine I et al (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10:115\u2013124","journal-title":"Lancet Oncol"},{"key":"1926_CR14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF01409478","volume":"38","author":"A Favero Del","year":"1990","unstructured":"Del Favero A, Roila F, Basurto C et al (1990) Assessment of nausea. Eur J Clin Pharmacol 38:115\u2013120","journal-title":"Eur J Clin Pharmacol"},{"key":"1926_CR15","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00520-011-1239-0","volume":"20","author":"K Aogi","year":"2012","unstructured":"Aogi K, Sakai H, Yoshizawa H et al (2012) A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy. Support Care Cancer 20:1507\u20131514","journal-title":"Support Care Cancer"},{"key":"1926_CR16","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1007\/s00520-012-1469-9","volume":"20","author":"V Lorusso","year":"2012","unstructured":"Lorusso V, Giampaglia M, Petrucelli L et al (2012) Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapy. Support Care Cancer 20:3241\u20136","journal-title":"Support Care Cancer"},{"key":"1926_CR17","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/bjc.1998.244","volume":"77","author":"R Wit de","year":"1998","unstructured":"de Wit R, van den Berg H, Burghouts J et al (1998) Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles. Br J Cancer 77:1487\u20131491","journal-title":"Br J Cancer"},{"key":"1926_CR18","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/cncr.21343","volume":"104","author":"J Herrstedt","year":"2005","unstructured":"Herrstedt J, Muss HB, Warr DG et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 104:1548\u20131555","journal-title":"Cancer"},{"key":"1926_CR19","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/oxfordjournals.annonc.a010675","volume":"7","author":"L Franzen","year":"1996","unstructured":"Franzen L, Nyman J, Hagberg H et al (1996) A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy. Ann Oncol 7:587\u2013592","journal-title":"Ann Oncol"},{"key":"1926_CR20","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1081\/CNV-100107736","volume":"19","author":"R Lanciano","year":"2001","unstructured":"Lanciano R, Sherman DM, Michalski J et al (2001) The efficacy and safety of once-daily Kytril (granisetron hydrochloride) tablets in the prophylaxis of nausea and emesis following fractionated upper abdominal radiotherapy. Cancer Investig 19:763\u2013772","journal-title":"Cancer Investig"},{"key":"1926_CR21","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0936-6555(05)80086-X","volume":"5","author":"TJ Priestman","year":"1993","unstructured":"Priestman TJ, Roberts JT, Upadhyaya BK (1993) A prospective randomized double-blind trial comparing ondansetron versus prochlorperazine for the prevention of nausea and vomiting in patients undergoing fractionated radiotherapy. Clin Oncol (R Coll Radiol) 5:358\u2013363","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"1926_CR22","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1002\/cncr.11433","volume":"97","author":"S Poli-Bigelli","year":"2003","unstructured":"Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090\u20133098","journal-title":"Cancer"},{"key":"1926_CR23","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1200\/JCO.2011.39.5558","volume":"30","author":"C Albany","year":"2012","unstructured":"Albany C, Brames MJ, Fausel C et al (2012) Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study. J Clin Oncol 30:3998\u20134003","journal-title":"J Clin Oncol"},{"key":"1926_CR24","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00520-007-0255-6","volume":"15","author":"LH Einhorn","year":"2007","unstructured":"Einhorn LH, Brames MJ, Dreicer R et al (2007) Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 15:1293\u20131300","journal-title":"Support Care Cancer"},{"key":"1926_CR25","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00520-006-0158-y","volume":"15","author":"J Herrstedt","year":"2007","unstructured":"Herrstedt J, Sigsgaard TC, Nielsen HA et al (2007) Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy. Support Care Cancer 15:417\u2013426","journal-title":"Support Care Cancer"},{"key":"1926_CR26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00520-008-0445-x","volume":"17","author":"A Enblom","year":"2009","unstructured":"Enblom A, Bergius Axelsson B, Steineck G et al (2009) One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient. Support Care Cancer 17:23\u201332","journal-title":"Support Care Cancer"},{"key":"1926_CR27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.radonc.2009.11.001","volume":"94","author":"E Maranzano","year":"2010","unstructured":"Maranzano E, De Angelis V, Pergolizzi S et al (2010) A prospective observational trial on emesis in radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centres. Radiother Oncol 94:36\u201341","journal-title":"Radiother Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-013-1926-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-013-1926-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-013-1926-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,20]],"date-time":"2019-07-20T19:17:02Z","timestamp":1563650222000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-013-1926-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,15]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["1926"],"URL":"https:\/\/doi.org\/10.1007\/s00520-013-1926-0","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2013,8,15]]}}}